Price Alert

Intercept Pharmaceuticals... (ICPT)

NASDAQ: ICPT · Real-Time Price · USD

19.00

0.04 (0.21%)

At close: Nov 07, 2023, 10:00 PM

Intercept Pharmaceuticals Statistics

Share Statistics

Intercept Pharmaceuticals has 41.83M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding	41.83M
Shares Change (YoY)	0%
Shares Change (QoQ)	0%
Owned by Institutions (%)	n/a
Shares Floating	34.49M
Failed to Deliver (FTD) Shares	584,432
FTD / Avg. Volume	28.45%

Short Selling Information

The latest short interest is 10.14M, so 24.23% of the outstanding shares have been sold short.

Short Interest	10.14M
Short % of Shares Out	24.23%
Short % of Float	25.18%
Short Ratio (days to cover)	8.34

Valuation Ratios

The PE ratio is 3.63 and the forward PE ratio is null. Intercept Pharmaceuticals's PEG ratio is -0.02.

PE Ratio	3.63
Forward PE	n/a
PS Ratio	1.46
Forward PS	n/a
PB Ratio	4.49
P/FCF Ratio	-15.3
PEG Ratio	-0.02

Financial Ratio History

Enterprise Valuation

Intercept Pharmaceuticals has an Enterprise Value (EV) of 700.53M.

EV / Sales	2.45
EV / EBITDA	-11.35
EV / EBIT	-26.16
EV / FCF	-25.62

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of 3.57.

Current Ratio	2.35
Quick Ratio	2.32
Debt / Equity	3.57
Debt / EBITDA	-5.39
Debt / FCF	-12.16
Interest Coverage	-3.19

Financial Efficiency

Return on Equity is 123.74% and Return on Invested Capital is 10.37%.

Return on Equity	123.74%
Return on Assets	20.8%
Return on Invested Capital	10.37%
Revenue Per Employee	$837.86K
Profits Per Employee	$337.75K
Employee Count	341
Asset Turnover	0.52
Inventory Turnover	0.15

Taxes

Income Tax	-290.03M
Effective Tax Rate	165.87%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is 0.88, so Intercept Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.88
52-Week Price Change	n/a
50-Day Moving Average	16.63
200-Day Moving Average	14.75
Relative Strength Index (RSI)	75.79
Average Volume (20 Days)	2,054,565

Income Statement

In the last 12 months, Intercept Pharmaceuticals had revenue of 285.71M and earned 115.17M in profits. Earnings per share was 3.41.

Revenue	285.71M
Gross Profit	284.73M
Operating Income	-68.22M
Net Income	115.17M
EBITDA	-61.7M
EBIT	-153.47M
Earnings Per Share (EPS)	3.41

Full Income Statement

Balance Sheet

The company has 50.52M in cash and 332.67M in debt, giving a net cash position of -282.16M.

Cash & Cash Equivalents	50.52M
Total Debt	332.67M
Net Cash	-282.16M
Retained Earnings	-2.14B
Total Assets	393.16M
Working Capital	292.6M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -26.78M and capital expenditures -568K, giving a free cash flow of -27.35M.

Operating Cash Flow	-26.78M
Capital Expenditures	-568K
Free Cash Flow	-27.35M
FCF Per Share	-0.81

Full Cash Flow Statement

Margins

Gross margin is 99.66%, with operating and profit margins of -23.88% and 40.31%.

Gross Margin	99.66%
Operating Margin	-23.88%
Pretax Margin	-61.2%
Profit Margin	40.31%
EBITDA Margin	-21.59%
EBIT Margin	-23.88%
FCF Margin	-9.57%

Dividends & Yields

ICPT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	27.53%
FCF Yield	-6.54%

Dividend Details

Analyst Forecast

Currently there are no analyst rating for ICPT.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	14.52
Graham Upside	-23.58%

Scores

Altman Z-Score	-5.01
Piotroski F-Score	3